Funding Rounds
CatalYm

CatalYm Series D (2024, $150M)

CatalYm

Innovative immunotherapies developer for cancer patients.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series D

Raised Amount: $150.00M

Investors